Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

A cow got gene therapy. Patients are still waiting | STAT (opens in a new tab)

A cow got gene therapy. Patients are still waiting · 2026-10-27

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 2 other points were not covered by the paper.

  • 1 supported
  • 1 overstated
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. One of four checks out. Two claims the study doesn't address.

  • 1 supported
  • 1 overstated
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4OverstatedThe goal of the work was to prove that an MSUD gene therapy could work and provide a one-time fix for families in the Mennonite community.View evidenceHide evidence

As statedtwo decades

Why this verdict

The paper supports a preclinical, one-time systemic dual-gene replacement approach in mice and one calf, and frames it as promising. The story’s language that the goal was to “prove” it could work and provide a “simple, one-time fix” for families in a Mennonite community outruns the abstract-level evidence, which is animal/preclinical and does not establish a human cure or community-level clinical benefit.

1

Study evidence

A single postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death in both Bckdha-/- and Bckdhb-/- mouse models of severe MSUD.

“In two models of severe MSUD (Bckdha-/- and Bckdhb-/- mice) ... one postnatal injection prevented perinatal death, normalized growth”
2

Study evidence

One postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death in a newborn calf homozygous for BCKDHA c.248C>T.

“...and a newborn calf homozygous for BCKDHA c.248C>T”
Claim 2 of 4Not coveredPetunia survived and is now described as a feisty, 5-year-old, hay-munching, 1,500 pound heifer.View evidenceHide evidence

As stated5-year-old, 1,500 pound

Why this verdict

The abstract-level profile supports survival/prevention of perinatal death and normalized growth in the treated calf. It does not provide the calf’s name, current age, weight, long-term health description, or the “feisty, hay-munching” characterization. Those long-term and anecdotal details may come from reporting outside the abstract, but they are not verifiable from the supplied paper profile.

1

Study evidence

One postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death in a newborn calf homozygous for BCKDHA c.248C>T.

“...and a newborn calf homozygous for BCKDHA c.248C>T”
Claim 3 of 4Not coveredNo patient of Kevin Strauss has received the treatment, not even in a clinical trial.View evidenceHide evidence

As statednot a single one

Why this verdict

The supplied paper profile is preclinical and contains no human-patient or clinical-trial unit, which is consistent with the treatment not yet being in patients. However, the specific claim that no patient of Kevin Strauss has received it, including in a clinical trial, is not directly established by the abstract-level profile and is therefore not verifiable at this depth.

Claim 4 of 4SupportedPetunia, a calf with bovine maple syrup urine disease, was kept alive and injected with a virus carrying new genes by three researchers.View evidenceHide evidence

As statedone calf

Why this verdict

The abstract-level paper profile supports the core scientific claim that a newborn calf with naturally occurring MSUD received a systemic rAAV9 gene-therapy vector carrying BCKDHA/BCKDHB and that treatment was associated with prevention of perinatal death. The abstract/profile does not verify the calf’s name, the exact wording “kept alive,” or that three researchers performed the injection, but the central treatment-and-survival claim is aligned with unit_0004.

1

Study evidence

One postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death in a newborn calf homozygous for BCKDHA c.248C>T.

“...and a newborn calf homozygous for BCKDHA c.248C>T”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • In vitro proof-of-mechanism: rAAV9.hA-BiP-hB restored BCKDHA/BCKDHB coexpression and BCKDH holoenzyme activity in BCKDHA-/- HEK293T cells.

    The story excerpt focuses on the calf and human-access narrative and does not mention the cellular validation work.

    From in_vitro rAAV9 transduction (HEK293T)

  • Wild-type mouse tolerability: systemic rAAV9.hA-BiP-hB at the tested dose did not perturb physiologic branched-chain amino acid homeostasis.

    The story does not mention the wild-type mouse safety/tolerability experiment or its limited biomarker scope.

    From in_vivo_single-dose_tolerability

  • Mouse efficacy: one postnatal systemic injection prevented perinatal death, normalized growth, restored multi-tissue BCKDHA/BCKDHB expression, and stabilized biomarkers in two severe MSUD mouse models.

    This is a primary paper contribution, but the presented story claims center on the calf and do not describe the two mouse models or their outcomes.

    From postnatal systemic rAAV9 dual-gene replacement in knockout mice

  • Important limitation: the abstract does not provide calf dosing details, quantitative outcome measures, control-comparison details, statistical analysis, long-term safety, toxicity, or immune-response data.

    The story’s caveat only notes that the excerpt lacks human-study details. It does not acknowledge these interpretation-changing preclinical-detail and safety limitations from the abstract-level profile.

    From Postnatal systemic rAAV9.hA-BiP-hB treatment in a naturally affected newborn calf

4 things the story did carry across
  • The paper’s core intervention is a dual-function systemic rAAV9 vector delivering codon-optimized BCKDHA and BCKDHB.
  • Large-animal translational result: a newborn calf homozygous for BCKDHA c.248C>T received one postnatal systemic injection and had survival, normalized growth, tissue expression, and biomarker stabilization outcomes.
  • Important limitation: the calf evidence in the abstract is a single described large-animal subject, limiting generalizability and reproducibility assessment.
  • Human clinical efficacy is not established by the paper profile; the supplied units are cell, mouse, wild-type mouse tolerability, and calf studies rather than human trials.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDemonstrate therapeutic efficacy of one-time postnatal systemic rAAV9.hA-BiP-hB in two severe MSUD mouse models (Bckdha-/- and Bckdhb-/-), preventing death and restoring systemic and tissue-level metabolic homeostasis, including under high protein ingestion.postnatal systemic rAAV9 dual-gene replacement in knockout miceExpand

In plain English

In two severe MSUD mouse models (Bckdha-/- and Bckdhb-/-), a single postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death, normalized growth, restored coordinated expression of BCKDHA and BCKDHB across skeletal muscle, liver, heart, and brain, and stabilized MSUD biomarkers during high-protein intake, supporting a one-time dual-gene replacement therapeutic approach.

Key findings

  • A single postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death in both Bckdha-/- and Bckdhb-/- mouse models of severe MSUD.
  • Treated knockout mice exhibited normalized growth after one postnatal systemic rAAV9.hA-BiP-hB injection.
“In two models of severe MSUD (Bckdha-/- and Bckdhb-/- mice) ... one postnatal injection prevented perinatal death, normalized growth”
What this piece can’t prove

4 further details could not be confirmed from the summary.

2in vitroDevelop and validate a dual-function systemic rAAV9 vector that co-delivers BCKDHA and BCKDHB and restores BCKDH holoenzyme activity (proof of mechanism in cells).in vitro rAAV9 transduction (HEK293T)Expand

In plain English

In BCKDHA-/- HEK293T cells, a dual-function rAAV9 vector (rAAV9.hA-BiP-hB) delivering codon-optimized BCKDHA and BCKDHB restored coexpression of both E1 subunits and recovered BCKDH holoenzyme activity, providing an in vitro proof-of-mechanism for the dual-gene vector.

Key findings

  • rAAV9.hA-BiP-hB restored coexpression of BCKDHA and BCKDHB and recovered BCKDH holoenzyme activity in BCKDHA-/- HEK293T cells.
“we designed a dual-function recombinant adeno-associated virus serotype 9 (rAAV9) vector to deliver codon-optimized BCKDHA and BCKDHB”
What this piece can’t prove
  • Summary is based solely on abstract text; full experimental details, quantitative outcomes, and statistical analyses are not available in the excerpt.
  • Use of HEK293T knockout cells limits assessment of relevance to primary human tissues or organ systems affected in MSUD.
  • No information in abstract about assay methods, sensitivity/specificity, transduction efficiency, or potential off-target effects.
3in vivo animalEstablish preclinical safety/physiologic tolerability of systemic rAAV9.hA-BiP-hB dosing in wild-type mice (no perturbation of branched-chain amino acid homeostasis at the tested dose).in vivo single-dose tolerabilityExpand

In plain English

In wild-type mice, a single systemic dose of rAAV9.hA-BiP-hB at 2.7 × 10^14 vector genomes/kg did not perturb physiologic branched-chain amino acid (BCAA) homeostasis, indicating tolerability with respect to the measured metabolic biomarkers in the abstracted study.

Key findings

  • A single systemic dose of rAAV9.hA-BiP-hB (2.7 × 10^14 vg/kg) did not perturb physiologic branched-chain amino acid homeostasis in wild-type mice (abstract).
“did not perturb physiologic branched-chain amino acid homeostasis in wild-type mice at a systemic dose of 2.7 × 10^14 vector genomes per kilogram”
What this piece can’t prove
  • Summary based solely on abstract statement; full manuscript may contain additional details not available here.
  • Abstract provides no quantitative data, sample sizes, timepoints, or assay descriptions for the reported BCAA measurements.

1 further detail could not be confirmed from the summary.

4in vivo animalDemonstrate translational feasibility/efficacy of the same approach in a naturally affected large-animal model (newborn calf homozygous for BCKDHA c.248C>T), with survival, growth, tissue expression, and biomarker stabilization outcomes.Postnatal systemic rAAV9.hA-BiP-hB treatment in a naturally affected newborn calfExpand

In plain English

A single newborn calf naturally homozygous for BCKDHA c.248C>T received one postnatal systemic injection of rAAV9.hA-BiP-hB. The treated calf did not experience perinatal death, exhibited normalized growth, showed coordinated restoration of BCKDHA and BCKDHB expression across skeletal muscle, liver, heart, and brain, and had stabilization of MSUD metabolic biomarkers despite high-protein intake, as reported in the paper abstract.

Key findings

  • One postnatal systemic injection of rAAV9.hA-BiP-hB prevented perinatal death in a newborn calf homozygous for BCKDHA c.248C>T.
  • Treated calf exhibited normalized growth following the single postnatal rAAV9.hA-BiP-hB injection.
“...and a newborn calf homozygous for BCKDHA c.248C>T”
What this piece can’t prove

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref · 15 candidate papers

Candidate

139. Human Amnion Epithelial (AE) Stem Cell Transplant Improves Disease Phenotype and Survival in Mouse Models of Intermediate Maple Syrup Urine Disease (MSUD)

Molecular Therapy · 2010 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.